Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biomedical research : information on federal contributions to remdesivir: report to congressional committees / / Candice N. Wright
| Biomedical research : information on federal contributions to remdesivir: report to congressional committees / / Candice N. Wright |
| Pubbl/distr/stampa | Washington, DC : , : United States Government Accountability Office, , 2021 |
| Descrizione fisica | 1 online resource (ii, 35 pages) : illustrations |
| Soggetto topico |
Antiviral agents - United States
COVID-19 (Disease) - Treatment |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Biomedical research |
| Record Nr. | UNINA-9910717171103321 |
| Washington, DC : , : United States Government Accountability Office, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Covid-19 : the essentials of prevention and treatment / / Jie-Ming Qu, Bin Cao, Rong-Chang Chen
| Covid-19 : the essentials of prevention and treatment / / Jie-Ming Qu, Bin Cao, Rong-Chang Chen |
| Autore | Qu Jie-Ming |
| Pubbl/distr/stampa | Amsterdam, The Netherlands ; ; Oxford, England ; ; Cambridge, Massachusetts : , : Elsevier, , [2021] |
| Descrizione fisica | 1 online resource (116 pages) |
| Disciplina | 616.2414 |
| Soggetto topico | COVID-19 (Disease) - Treatment |
| ISBN | 0-12-824251-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910583080403321 |
Qu Jie-Ming
|
||
| Amsterdam, The Netherlands ; ; Oxford, England ; ; Cambridge, Massachusetts : , : Elsevier, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COVID-19 : current challenges and future perspectives / / edited by Anoop Kumar
| COVID-19 : current challenges and future perspectives / / edited by Anoop Kumar |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers, , [2021] |
| Descrizione fisica | 1 online resource (212 pages) |
| Disciplina | 614.592414 |
| Soggetto topico | COVID-19 (Disease) - Treatment |
| ISBN | 981-14-9864-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910794692403321 |
| Singapore : , : Bentham Science Publishers, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COVID-19 : current challenges and future perspectives / / edited by Anoop Kumar
| COVID-19 : current challenges and future perspectives / / edited by Anoop Kumar |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers, , [2021] |
| Descrizione fisica | 1 online resource (212 pages) |
| Disciplina | 614.592414 |
| Soggetto topico | COVID-19 (Disease) - Treatment |
| ISBN | 981-14-9864-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910819693503321 |
| Singapore : , : Bentham Science Publishers, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COVID-19 critical and intensive care medicine essentials / / Denise Battaglini and Paolo Pelosi, editors
| COVID-19 critical and intensive care medicine essentials / / Denise Battaglini and Paolo Pelosi, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer International Publishing, , [2022] |
| Descrizione fisica | 1 online resource (308 pages) |
| Disciplina | 362.1962414 |
| Soggetto topico |
COVID-19 (Disease) - Treatment
Emergency medicine |
| ISBN | 3-030-94992-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- Part I: Fundamentals of COVID-19 -- 1: Essential Multiorgan Pathophysiology of COVID-19 -- 1.1 Introduction -- 1.2 Structure of SARS-CoV-2 Host Cell Infection and Systemic Replication -- 1.3 Respiratory System -- 1.4 Cardiovascular System -- 1.5 Coagulation Disorders -- 1.6 Kidney Injury -- 1.7 Gastrointestinal System -- 1.8 Nervous System -- 1.9 Other Manifestations -- 1.10 Conclusions -- References -- Part II: Pneumological Critical Care of COVID-19 -- 2: Clinical Presentation and Phenotypes in COVID-19 -- 2.1 Introduction -- 2.2 Definition of Phenotypes -- 2.2.1 Phenotype L (or Phenotype 1) -- 2.2.2 Phenotype 2 -- 2.2.3 Phenotype H (or Phenotype 3) -- 2.2.4 Phenotype F -- 2.3 Clinical Message and Conclusions -- References -- 3: Radiological Patterns and Lung Ultrasound -- 3.1 Introduction -- 3.1.1 Imaging Strategy -- 3.2 Diagnostic Imaging -- 3.2.1 Radiological Imaging -- 3.2.2 Chest High Resolution Computed Tomography (HRCT) -- 3.2.3 COVID-19 Chest CT Phenotypes -- 3.2.4 Quantitative Computed Tomography (QCT) -- 3.2.5 Lung Ultrasound -- References -- 4: Noninvasive Mechanical Ventilation and Conventional Oxygen Therapy -- 4.1 Introduction -- 4.2 Noninvasive Ventilation in Non-COVID-19 ARF -- 4.3 Noninvasive Ventilation and Oxygenation Strategies in COVID-19 Pneumonia Presenting with Hypoxemic ARF -- 4.4 Safety -- References -- 5: Indications for Intubation in COVID-19 -- 5.1 Introduction -- 5.2 Technical Aspects and Operator Safety Concerns -- 5.3 Clinical Context and Rationale for Intubation -- 5.4 Criteria for Intubation in COVID-19 -- 5.5 Conclusions -- References -- 6: Invasive Mechanical Ventilation in COVID-19 -- 6.1 Introduction -- 6.2 Tidal Volume -- 6.3 Plateau and Driving Pressure -- 6.4 Peep and Recruitment Maneuvers -- 6.5 Fraction of Inspired Oxygen.
6.6 Rescue Strategies -- 6.7 Clinical Message and Conclusions -- References -- 7: Weaning, Tracheostomy, and Chest Physiotherapy -- 7.1 Weaning from Mechanical Ventilation in COVID-19 Patients -- 7.2 Tracheostomy in COVID-19 Patients -- 7.3 Chest Physiotherapy in COVID-19 -- References -- Part III: Neurological Manifestations of COVID-19 -- 8: Neuropathogenesis and Neurological Manifestations of SARS-CoV-2 -- 8.1 Current Neuropathogenic Hypotheses -- 8.1.1 Transcribial Spread -- 8.1.2 Hematogenous Pathway -- 8.2 Mechanisms of Neurological Complications -- 8.2.1 Ischemic Stroke -- 8.2.2 Intracranial Hemorrhage -- 8.2.3 Delirium -- 8.2.4 Immune-Mediated Diseases: Autoimmune Encephalitis, Guillain-Barré Syndrome, Transverse Myelitis, and Neuropathy -- 8.2.5 Direct Infection-Encephalitis -- 8.3 Conclusions and Clinical Considerations -- References -- 9: Clinical Characteristics -- 9.1 Clinical Characteristics of COVID-19 -- 9.2 Central Nervous System Manifestations of COVID-19 -- 9.2.1 Ischaemic Stroke -- 9.2.2 Intracranial Haemorrhage (ICH) -- 9.2.3 Encephalopathy -- 9.2.4 Encephalitis and Meningitis -- 9.2.5 Transverse Myelitis -- 9.2.6 Seizures -- 9.3 Peripheral Nervous System Manifestations of COVID-19 -- 9.3.1 Guillain-Barré Syndrome and Miller Fisher Syndrome -- 9.3.2 Other Peripheral Neuropathies -- 9.3.3 Myasthenia Gravis -- 9.4 Conclusions -- References -- 10: The Role of Noninvasive Multimodal Neuromonitoring -- 10.1 Background -- 10.2 Clinical Features -- 10.3 Noninvasive Multimodal Neuromonitoring in COVID-19 -- 10.3.1 Brain Ultrasonography -- 10.3.2 Near Infrared Spectroscopy -- 10.3.3 Automated Pupillometer -- 10.3.4 Electroencephalogram -- 10.4 Conclusions -- References -- 11: Management of Neurological Complications -- 11.1 Introduction -- 11.2 Encephalopathy/Delirium. 11.3 Effect of Prophylactic Anticoagulation on Neurological Conditions -- 11.4 Ischemic Stroke -- 11.5 Intracranial Hemorrhage -- 11.6 Peripheral Nerve and Muscle Injury -- 11.7 Special Consideration: Severe ARDS and ECMO -- 11.8 Conclusions -- References -- Part IV: Cardiovascular Manifestations of COVID-19 -- 12: Brief Pathophysiology -- References -- 13: Biomarkers, Electrocardiography, and Echocardiography -- 13.1 Biomarkers -- 13.2 Cardiac Troponin -- 13.3 Natriuretic Peptides -- 13.4 d-Dimer -- 13.5 Electrocardiography -- 13.6 Echocardiography -- References -- 14: Clinical Characteristics -- 14.1 Venous Thromboembolism and Pulmonary Embolism -- 14.2 Heart Failure and Cardiogenic Shock -- 14.3 Acute Myocarditis -- 14.4 Acute Coronary Syndromes and Takotsubo Syndrome -- 14.5 Cardiac Arrhythmias and Cardiac Arrest -- 14.6 Multisystem Inflammatory Disorder in Children (MIS-C) -- 14.7 Long COVID-19 -- References -- 15: Management -- 15.1 CV Comorbidities -- 15.2 Venous and Pulmonary Thromboembolism -- 15.2.1 Acute Coronary Syndromes (ACS) -- 15.2.2 Myocarditis -- 15.2.3 Cardiac Arrhythmias -- References -- Part V: Renal Manifestations of COVID-19 -- 16: Brief Pathophysiology -- 16.1 Introduction -- 16.2 SARS-CoV-2 and COVID-19 Pathophysiology -- 16.3 ACE-2 Receptors and Direct Tubular Damage Hypothesis -- 16.4 Indirect Causes of AKI -- 16.4.1 Kidney-Lung Cross Talk -- 16.4.2 Cytokine Storm -- 16.4.3 Hypoperfusion -- 16.4.4 Hypercoagulability -- 16.4.5 Rhabdomyolysis -- 16.5 Conclusions -- References -- 17: Clinical Features and Biomarkers -- 17.1 Introduction -- 17.2 COVID-19 and Acute Kidney Injury -- 17.3 COVID-19 and Chronic Kidney Disease -- 17.4 COVID-19 and Kidney Transplantation -- 17.5 Renal Biomarkers in AKI and COVID-19 -- 17.6 Conclusions -- References -- 18: COVID-19 and Renal Replacement Therapies. 18.1 Introduction, Incidence, and Outcomes -- 18.2 Availability of Dialysis Machines and Resource Shortages -- 18.3 RRT in C-19-AKI: Rational and (Standard) Modalities -- 18.4 RRT in C-19-AKI: Rational and (Special) Modalities for Cytokines Clearance -- 18.5 Anticoagulation Strategies, Thrombogenicity and Filter Clotting -- 18.6 Conclusions -- References -- Part VI: Haemostasis and Coagulation in COVID-19 -- 19: Pathophysiology of Coagulopathy in COVID-19 -- 19.1 Introduction -- 19.2 Link Between Acute Inflammation and Coagulation Activation in Viral Infection -- 19.3 Critical Role of Endothelial Cell Infection in COVID-19 -- 19.4 Release of Extracellular Vesicle Tissue Factor, Procoagulant Enzymes, and Fibrinogen -- 19.5 Excess Thrombin Generation -- 19.6 Depletion of Endogenous Anticoagulants -- 19.7 Role of VWF -- 19.8 Increased Tissue Megakaryocytes and Increased Platelet Reactivity -- 19.9 Progressively Impaired Fibrinolysis -- References -- 20: Coagulation Disorders and Management -- 20.1 Coagulation Disorders -- 20.1.1 d-Dimer, Fibrinogen, and Standard Coagulation Tests -- 20.1.2 Viscoelastic Tests -- 20.2 Management -- References -- Part VII: Other Multiorgan Involvements -- 21: Gastrointestinal Manifestations of COVID-19 -- 21.1 Introduction -- 21.2 Pathogenesis -- 21.3 Clinical Manifestations -- 21.4 Hepatic Manifestations -- 21.5 Less Common Gastrointestinal Manifestations -- 21.6 Gastrointestinal Complications Associated with COVID-19 -- 21.7 Clostridioides difficile Infection -- 21.8 Pediatric Population -- 21.9 Conclusions -- References -- 22: Nutritional Therapy -- 22.1 Introduction -- 22.2 Nutritional Assessment -- 22.3 Timing and Route of Nutrition Delivery -- 22.4 Dose and Formula Selection -- References -- Part VIII: Principles of Therapy -- 23: Sedation, Analgesia, and Myorelaxants -- References. 24: Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2 -- 24.1 Antibiotics -- 24.2 Antiviral Therapy -- 24.3 Anti-Inflammatory Therapy -- 24.3.1 Corticosteroids -- 24.3.2 Tocilizumab -- 24.3.3 Other Immunomodulatory Therapies -- 24.4 Combined Therapy -- 24.5 Other Therapies -- 24.5.1 COVID-19 Convalescent Plasma -- 24.5.2 Stem Cell Therapy -- 24.6 Final Comments -- References -- 25: Coagulation and Haemostasis -- 25.1 Introduction -- 25.2 Thromboprophylaxis -- 25.3 Treatment of COVID-19-Associated Coagulation -- 25.4 Haemostasis -- 25.5 Conclusion -- References -- 26: Rescue Therapies -- 26.1 Prone Positioning -- 26.2 Extracorporeal Membrane Oxygenation (ECMO) and Extracorporeal CO2 Removal (ECCO2R) -- 26.3 Inhaled Nitric Oxide (INO) -- 26.4 Renal Replacement Therapy (RRT) -- References. |
| Record Nr. | UNINA-9910585787803321 |
| Cham, Switzerland : , : Springer International Publishing, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Covid-19 pandemic and the U.S. international response : hearing before the Committee on Foreign Relations, United States Senate, One Hundred Seventeenth Congress, first session, May 12, 2021
| Covid-19 pandemic and the U.S. international response : hearing before the Committee on Foreign Relations, United States Senate, One Hundred Seventeenth Congress, first session, May 12, 2021 |
| Pubbl/distr/stampa | Washington : , : U.S. Government Publishing Office, , 2021 |
| Descrizione fisica | 1 online resource (iii, 62 pages) : illustration |
| Collana | S. hrg. |
| Soggetto topico |
COVID-19 Pandemic, 2020-
COVID-19 (Disease) - Vaccination - International cooperation COVID-19 (Disease) - Prevention - International cooperation COVID-19 (Disease) - Treatment |
| Soggetto genere / forma | Legislative hearings. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Covid-19 pandemic and the U.S. international response |
| Record Nr. | UNINA-9910716992503321 |
| Washington : , : U.S. Government Publishing Office, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COVID-19: critical vaccine distribution, supply chain, program integrity, and other challenges require focused federal attention : report to congressional committees
| COVID-19: critical vaccine distribution, supply chain, program integrity, and other challenges require focused federal attention : report to congressional committees |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2021 |
| Descrizione fisica | 1 online resource (vii, 333 pages) : color illustrations |
| Soggetto topico |
COVID-19 (Disease) - Vaccination - United States - Planning
COVID-19 (Disease) - Economic aspects - United States COVID-19 (Disease) - Diagnosis - United States COVID-19 (Disease) - United States - Prevention COVID-19 (Disease) - Treatment - United States Vaccines industry - Government policy - United States Vaccines - Development - United States Public health administration - United States COVID-19 (Disease) - Diagnosis COVID-19 (Disease) - Economic aspects COVID-19 (Disease) - Prevention COVID-19 (Disease) - Treatment Expenditures, Public Public health administration Vaccines industry - Government policy |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | COVID-19 |
| Record Nr. | UNINA-9910715226403321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hybrid hearing with Secretary of Health and Human Services Alex M. Azar II : hearing before the Select Subcommittee on the Coronavirus Crisis of the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, second session, October 2, 2020
| Hybrid hearing with Secretary of Health and Human Services Alex M. Azar II : hearing before the Select Subcommittee on the Coronavirus Crisis of the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, second session, October 2, 2020 |
| Pubbl/distr/stampa | Washington : , : U.S. Government Publishing Office, , 2020 |
| Descrizione fisica | 1 online resource (iii, 53 pages) |
| Soggetto topico |
COVID-19 (Disease) - Diagnosis - United States
COVID-19 (Disease) - Treatment - United States Medical supplies - United States Vaccines - United States Emergency management - United States COVID-19 (Disease) - Diagnosis COVID-19 (Disease) - Treatment Emergency management Medical supplies Vaccines |
| Soggetto genere / forma | Legislative hearings. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Hybrid hearing with Secretary of Health and Human Services Alex M. Azar II |
| Record Nr. | UNINA-9910715175103321 |
| Washington : , : U.S. Government Publishing Office, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Post COVID-19 complications and management / / Anant Mohan and Saurabh Mittal, editors
| Post COVID-19 complications and management / / Anant Mohan and Saurabh Mittal, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (183 pages) : illustrations (black and white, and color) |
| Disciplina | 614.592414 |
| Soggetto topico |
COVID-19 (Disease) - Treatment
COVID-19 (Disease) - Complications - Treatment COVID-19 - complications COVID-19 - therapy |
| ISBN | 981-19-4407-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | COVID-19: An Overview -- Pulmonary Sequelae of COVID-19 -- Role of Imaging in Post-COVID-19 Complications -- Cardiovascular Complications Following COVID-19 -- Neurological Sequelae of COVID-19 -- Psychiatric Issues After COVID-19 -- Gastrointestinal and Hepatobiliary Complications Following COVID-19 -- Post-COVID-19 Endocrine Abnormalities -- Renal Abnormalities Following COVID-19 -- COVID-19 Sequelae Affecting Ear, Nose and Throat -- Rheumatological Complications Following COVID-19 -- Dermatological Sequelae of COVID-19 -- Eye Complications Following COVID-19 -- Role of Rehabilitation in the Post-COVID-19 Period -- Palliative Care Issues in Post-COVID-19. |
| Record Nr. | UNINA-9910624394803321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reviewing federal and state pandemic supply preparedness and response : joint hearing before the Subcommittee on Oversight, Management, and Accountability and the Subcommittee on Emergency Preparedness, Response, and Recovery, House of Representatives, One Hundred Sixteenth Congress, second session, July 14, 2020
| Reviewing federal and state pandemic supply preparedness and response : joint hearing before the Subcommittee on Oversight, Management, and Accountability and the Subcommittee on Emergency Preparedness, Response, and Recovery, House of Representatives, One Hundred Sixteenth Congress, second session, July 14, 2020 |
| Pubbl/distr/stampa | Washington : , : U.S. Government Publishing Office, , 2021 |
| Descrizione fisica | 1 online resource (iii, 51 pages) : color illustration |
| Soggetto topico |
COVID-19 (Disease) - United States - Prevention
COVID-19 (Disease) - Treatment - United States Medical supplies - United States Emergency management - United States COVID-19 (Disease) - Prevention COVID-19 (Disease) - Treatment Emergency management Medical supplies |
| Soggetto genere / forma | Legislative hearings. |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Reviewing federal and state pandemic supply preparedness and response |
| Record Nr. | UNINA-9910715976703321 |
| Washington : , : U.S. Government Publishing Office, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
